Dora Games, Ph.D.
Recent news about Alzheimer’s disease has ranged from hopeful to discouraging. There is a need for greater awareness and research funds. While brain scans and other tests are helping researchers detect disease symptoms earlier, recent failed drug trials have renewed the debate over what causes this devastating disease.
Dr. Dora Games joins the show with some updated info on recent breakthroughs in the understanding of the biology of Alzheimer's Disease.
Dr. Dora Games of Elan Pharmaceuticals has focused on the use of transgenic and other models of neurodegenerative diseases to test the efficacy of potential therapeutics. Over the past several years, her work has focused on the characterization of various immunotherapeutic approaches for Alzheimer’s disease, some which are currently in clinical trials. These studies enabled outcome measures in preclinical models that differentiate both the efficacy and potential clinical applications of these immunotherapies. Currently she is Vice President of Pharmacology at Neotope Biosciences, a division of Elan Pharmaceuticals.
Dr. Derrick DeSilva